Medical Oncology Board Review Course 2017 (The Passmachine) (Videos)

Please log in to view product prices.

Category:

Medical Oncology Board Review Course 2017 (The Passmachine) (Videos)

Intended Audience: Oncologists

Learning Objectives: 
Upon completion of this program, participants should be able to:

  • Assess diagnosis, staging and prognostic factors of breast cancer.
  • Explain the different types of gynecologic cancer.
  • Describe basic pharmacological and biological principles in the management and treatment of cancer.
  • Develop comprehensive management and treatment plans for genitourinary cancer including bladder, other urothelial, prostate, and renal cancer, and germ cell tumors.
  • Demonstrate medical management of lung and thymic cancer and mesothelioma.
  • Integrate modalities of care and ethics including treatment-related issues, complications, supportive care, survivorship, psychosocial aspects of cancer, bioethical/legal/economic issues, and communication skills.

Accreditation Statement:
This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of PeerPoint Medical Education Institute and American Physician Institute for Advanced Professional Studies, LLC. PeerPoint Medical Education Institute is accredited by the ACCME to sponsor continuing medical education for physicians.

MOC Accreditation Statement:
Successful completion of this CME activity enables the participant to earn up to 34.25 MOC points in the American Board of Internal Medicine’s (ABIM®) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM® MOC points.

Designation Statement:
Online Course v4.1, Release Date October 15, 2017, Termination Date October 14, 2020:
The PeerPoint Medical Education Institute designates this enduring material for a maximum of 34.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Question Bank, Release Date April 1, 2018, Termination Date April 1, 2021:
The PeerPoint Medical Education Institute designates this enduring material for a maximum of 41.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Nurse Practitioners: For all your CE requirements for recertification, the ANCC will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Physician Assistants: The NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

LASER-FOCUSED LECTURES: The Pass Machine Medical Oncology board review course will help you master the ABIM® exam material quickly and easily. This course features a comprehensive library of short video lectures that are precisely aligned to the Medical Oncology Certification and Medical Oncology MOC exam blueprints. This way, you’ll focus on all of the exam topics and keywords with no wasted effort.

THE “QBL” METHOD: “Question-Based Learning” ensures that your review is 100% relevant to the ABIM® Medical Oncology exam. This proven method works by pairing multiple choice questions with related lectures, allowing you to review a topic before answering the corresponding question.

BOARD-EXPERIENCED FACULTY:  The Medical Oncology Certification and Medical Oncology MOC courses feature board-certified faculty experienced in teaching Medical Oncology board exam preparation. Thus, every lecture is up-to-date, medically accurate and entirely board-relevant.

Topics/Speaker:

Hematologic Neoplasms
Acute Leukemia and Myelodysplasia (1 Hour)
Peter Silberstein, MD
Chronic Myeloid Leukemia and Myeloproliferative Neoplasms (.75 Hour)
Peter Silberstein, MD
Chronic Lymphoproliferative Leukemias (.75 Hour)
Peter Silberstein, MD
Hodgkin Lymphoma (.25 Hour)
Peter Silberstein, MD
Multiple Myeloma and Plasma Cell Dyscrasias (.75 Hour)
Peter Silberstein, MD
Non-Hodgkin Lymphoma (1.5 Hours)
Peter Silberstein, MD
Thoracic Cancer
Non-small cell lung cancer (3.25 Hours)
Sridhar Mani, MD
Small Cell Lung Cancer (.25 Hour)
Sridhar Mani, MD
Mesothelioma and Thymus Cancer (.25 Hour)
Sridhar Mani, MD
Breast Cancer
Premalignant Conditions and High-Risk Factors (.25 Hour)
Lea Baer, MD
Carcinoma in Situ (.25 Hour)
Lea Baer, MD
Early-Stage Invasive Carcinoma (1.75 Hours)
Lea Baer, MD
Locally advanced and inflammatory disease (.25 Hour)
Lea Baer, MD
Locally Recurrent Disease (.25 Hour)
Lea Baer, MD
Metastatic Disease (1.5 Hours)
Lea Baer, MD
Less Common Histologies and Clinical Scenarios (.25 Hour)
Lea Baer, MD
Genitourinary Cancer
Germ Cell Tumors (.25 Hour)
Terence Friedlander, MD
Prostate Cancer (1.75 Hours)
Terence Friedlander, MD
Renal Cell Cancer (1 Hour)
Terence Friedlander, MD
Urothelial and other Genitorourinary cancers (1 Hour)
Terence Friedlander, MD
Gynecologic Cancer
Cancer of the Cervix, Vulva, and Vagina (.25 Hour)
Peter Silberstein, MD
Ovarian, Fallopian Tube, and Primary Peritoneal Cancers (1 Hour)
Peter Silberstein, MD
Other Gynecologic Malignancies (.25 Hour)
Peter Silberstein, MD
Gastrointestinal Cancer
Gastrointestinal – Colorectal Cancer (1 Hour)
Michael Morse, MD
Gastrointestinal – Esophageal and Gastric Cancer (1 Hour)
Michael Morse, MD
Gastrointestinal – Hepatocellular and Biliary Gallbladder Cancer and Neuroendocrine Tumors (1 Hour)
Michael Morse, MD
Gastrointestinal – Pancreatic and Anal Cancer (1 Hour)
Michael Morse, MD
Skin Cancer, Sarcomas, and Unknown Primary Site
Melanoma (.25 Hour)
Natalya Mar, MD
Other Skin Cancers (.25 Hour)
Natalya Mar, MD
Bone and Soft-Tissue Sarcomas (.25 Hour)
Natalya Mar, MD
Unknown Primary Site (1.25 Hours)
Natalya Mar, MD
Anticancer Therapeutics, Clinical Research Methodology, and Ethics
Principles of Allied Disciplines (.25 Hour)
Sridhar Mani, MD
Anticancer Therapeutics (3 Hours)
Sridhar Mani, MD
Clinical Research Methodology and Ethics (.25 Hour)
Sridhar Mani, MD
Supportive Care, Survivorship, and Communication
Clinical Manifestations of advanced cancer and its treatment (1.5 Hours)
Peter Silberstein, MD
Cancer Pain (.75 Hour)
Peter Silberstein, MD
Survivorship Issues (.25 Hour)
Peter Silberstein, MD
End of Life Issues (.75 Hour)
Peter Silberstein, MD
Procedure-related issues (.25 Hour)
Peter Silberstein, MD
Communication (.25 Hour)
Peter Silberstein, MD
Head, Neck, Thyroid, and Central Nervous System Malignancies
Head and Neck Cancer, Thyroid Cancer, Salivary Gland (1 Hour)
Tanguy Seiwert, MD
Genetics and Tumor Biology
Cancer Biology and Genetics (.5 Hour)
Sridhar Mani, MD

Related Products